Carbapenem-resistant Pseudomonas aeruginosa
% Resistant in 2024
13.0% Resistant
Number of Resistant Isolates of the Total Number of Isolates Tested In 2024
877 Resistant
/ 6,738 Tested
% Resistant by Patient Age in 2024
- Pediatric:
- 10.9% Resistant
- Adult:
- 13.1% Resistant
Pathogen Profile
Carbapenem-resistant Pseudomonas aeruginosa
Pseudomonas aeruginosa is a common cause of healthcare-associated infections including pneumonia, bloodstream infections, urinary tract infections, and surgical site infections. P. aeruginosa are becoming more resistant to even antibiotics of last resort, such as carbapenems.
- Data Source
- National Healthcare Safety Network (NHSN)
- Current Threat Report
Threat LevelNot Currently Rated
Source: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2024
- Years Included
- 2011 - 2024
Geographic Locations
Percent Carbapenem resistance Among Pseudomonas aeruginosa by State Map
Percent Carbapenem resistance Among Pseudomonas aeruginosa by State
| Location | value |
|---|---|
| Alabama | 20.8 |
| Alaska | Insufficient Data |
| Arizona | 9.1 |
| Arkansas | 11.9 |
| California | 11.4 |
| Colorado | 5.9 |
| Connecticut | 7.9 |
| Delaware | Insufficient Data |
| District of Columbia | 25 |
| Florida | 13.2 |
| Georgia | 17.5 |
| Hawaii | 11.1 |
| Idaho | 7.7 |
| Illinois | 14 |
| Indiana | 12.2 |
| Iowa | 8.5 |
| Kansas | 2.9 |
| Kentucky | 20.5 |
| Louisiana | 11.1 |
| Maine | 10 |
| Maryland | 14.4 |
| Massachusetts | 15.6 |
| Michigan | 10.3 |
| Minnesota | 13 |
| Mississippi | 14.5 |
| Missouri | 10.7 |
| Montana | Insufficient Data |
| Nebraska | 4.9 |
| Nevada | 21.4 |
| New Hampshire | Insufficient Data |
| New Jersey | 15.8 |
| New Mexico | 11.9 |
| New York | 14.5 |
| North Carolina | 13.7 |
| North Dakota | Insufficient Data |
| Ohio | 16.5 |
| Oklahoma | 8.7 |
| Oregon | 20.8 |
| Pennsylvania | 10.5 |
| Puerto Rico | 34.8 |
| Rhode Island | 3.1 |
| South Carolina | 13.4 |
| South Dakota | 25 |
| Tennessee | 11.9 |
| Texas | 15.4 |
| Utah | 19.2 |
| Vermont | Insufficient Data |
| Virginia | 4.8 |
| Washington | 10.5 |
| West Virginia | 3.2 |
| Wisconsin | 9.2 |
| Wyoming | Insufficient Data |
Percent Carbapenem resistance Among Pseudomonas aeruginosa by State List
Geography
| state | value |
|---|---|
| United States | 13.0% |
| Alabama | 20.8% |
| Alaska | No Data |
| Arizona | 9.1% |
| Arkansas | 11.9% |
| California | 11.4% |
| Colorado | 5.9% |
| Connecticut | 7.9% |
| Delaware | No Data |
| District of Columbia | 25.0% |
Changes Over Time in Carbapenem resistance Among Pseudomonas aeruginosa
This graph displays percent antimicrobial resistance from 2011 to 2024 for all event types. Blank areas of the chart represent 0% resistance, indicating that zero resistant pathogens were reported for the selected year, phenotype, and HAI type. “Insufficient data” indicates that less than 20 pathogens were isolated and tested for resistance.
| Year | % Resistant |
|---|---|
| 2011 | 20 |
| 2012 | 17.8 |
| 2013 | 20.4 |
| 2014 | 19.2 |
| 2015 | 19.4 |
| 2016 | 18.4 |
| 2017 | 16.4 |
| 2018 | 14.3 |
| 2019 | 13.3 |
| 2020 | 12.9 |
| 2021 | 14 |
| 2022 | 14.2 |
| 2023 | 12.6 |
| 2024 | 13 |
Healthcare Facility Type
Carbapenem resistance Among Pseudomonas aeruginosa by Hospital Type
Percent resistant Among Pseudomonas aeruginosa by Hospital Type
| Hospital Type | % Resistant |
|---|---|
| General Acute Care Hospitals | 12.1 |
| Long Term Acute Care Hospitals | 31.7 |
| Inpatient Rehabilitation Facilities | 10.4 |
Footnotes
- HAIs include Catheter-associated Urinary Tract Infections (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), and Surgical Site Infections (SSI).
- CI (Confidence Interval) - The national, regional, and state-level data included in Antimicrobial Resistance information are displayed with 95% confidence intervals around the percent resistance, which were calculated using a mid-P exact test and are an indication of precision.
- Map legends are classified using the Jenks Natural Breaks method.